These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9629473)

  • 41. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.
    Avram S; Bologa C; Flonta ML
    J Mol Model; 2005 Mar; 11(2):105-15. PubMed ID: 15714296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs.
    Wong YN; Burcham DL; Saxton PL; Erickson-Viitanen S; Grubb MF; Quon CY; Huang SM
    Biopharm Drug Dispos; 1994 Oct; 15(7):535-44. PubMed ID: 7849230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
    Surleraux DL; Tahri A; Verschueren WG; Pille GM; de Kock HA; Jonckers TH; Peeters A; De Meyer S; Azijn H; Pauwels R; de Bethune MP; King NM; Prabu-Jeyabalan M; Schiffer CA; Wigerinck PB
    J Med Chem; 2005 Mar; 48(6):1813-22. PubMed ID: 15771427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation.
    Bai X; Yang Z; Zhu M; Dong B; Zhou L; Zhang G; Wang J; Wang Y
    Eur J Med Chem; 2017 Sep; 137():30-44. PubMed ID: 28554091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
    Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
    J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
    Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
    Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
    Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
    J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
    Kempf DJ; Sham HL; Marsh KC; Flentge CA; Betebenner D; Green BE; McDonald E; Vasavanonda S; Saldivar A; Wideburg NE; Kati WM; Ruiz L; Zhao C; Fino L; Patterson J; Molla A; Plattner JJ; Norbeck DW
    J Med Chem; 1998 Feb; 41(4):602-17. PubMed ID: 9484509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Studies of human immunodeficiency virus type 1 (HIV-1) protease inhibitors. III. Structure-activity relationship of HIV-1 protease inhibitors containing cyclohexylalanylalanine hydroxyethylene dipeptide isostere.
    Sakurai M; Higashida S; Sugano M; Handa H; Komai T; Yagi R; Nishigaki T; Yabe Y
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):534-40. PubMed ID: 8004698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
    Boyer FE; Vara Prasad JV; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Markoski LJ; Tait BD; Lunney EA; Palovsky A; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Sanders JM; VanderRoest S; Brodfuehrer J; Iyer K; Sinz M; Gulnik SV
    J Med Chem; 2000 Mar; 43(5):843-58. PubMed ID: 10715152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
    Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
    Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
    Kiso Y
    Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
    [No Abstract]   [Full Text] [Related]  

  • 55. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
    Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
    J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors.
    Hilgeroth A
    Mini Rev Med Chem; 2002 Jun; 2(3):235-45. PubMed ID: 12370065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
    Kaltenbach RF; Patel M; Waltermire RE; Harris GD; Stone BR; Klabe RM; Garber S; Bacheler LT; Cordova BC; Logue K; Wright MR; Erickson-Viitanen S; Trainor GL
    Bioorg Med Chem Lett; 2003 Feb; 13(4):605-8. PubMed ID: 12639540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
    Gao BL; Zhang CM; Yin YZ; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3730-3. PubMed ID: 21555220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.